Krystal Biotech (NASDAQ:KRYS) Releases Quarterly Earnings Results, Beats Expectations By $0.38 EPS

Key Points

• Krystal Biotech reported quarterly EPS of $1.83, beating the consensus by $0.38, and revenue of $116.36M, while showing strong profitability with a net margin 52.64% and ROE 18.69%.
• Shares trade around $266 with a market cap of $7.83B and a PE of ~38.8, and Wall Street is broadly bullish (nine Buys, two Holds) with a consensus price target of about $326.25.
• Insiders have sold 129,164 shares worth roughly $34.5M in the past 90 days, though company insiders still own about 13.10% of the stock.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) announced its earnings results on Monday. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.38, FiscalAI reports. The business had revenue of $116.36 million during the quarter, compared to analysts' expectations of $112.11 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $266.04 on Monday. The firm has a 50 day simple moving average of $261.72 and a 200 day simple moving average of $246.50. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $298.30. The company has a market cap of $7.83 billion, a PE ratio of 38.84 and a beta of 0.50.

Insider Activity

In other news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the transaction, the chief accounting officer owned 22,366 shares in the company, valued at approximately $5,985,141.60. The trade was a 3.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel Janney sold 11,803 shares of the company's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $275.59, for a total value of $3,252,788.77. Following the transaction, the director directly owned 73,293 shares in the company, valued at $20,198,817.87. The trade was a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 129,164 shares of company stock valued at $34,538,578 in the last 90 days. Company insiders own 13.10% of the company's stock.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently bought and sold shares of the business. Greenline Wealth Management LLC purchased a new position in Krystal Biotech during the 4th quarter valued at about $34,000. Danske Bank A S purchased a new stake in shares of Krystal Biotech in the third quarter worth approximately $35,000. UMB Bank n.a. boosted its holdings in shares of Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company's stock worth $36,000 after purchasing an additional 37 shares during the period. Global Retirement Partners LLC boosted its holdings in shares of Krystal Biotech by 788.9% during the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company's stock worth $39,000 after purchasing an additional 142 shares during the period. Finally, Osaic Holdings Inc. grew its position in Krystal Biotech by 41.4% during the second quarter. Osaic Holdings Inc. now owns 393 shares of the company's stock valued at $54,000 after purchasing an additional 115 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on KRYS shares. Guggenheim boosted their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Weiss Ratings raised shares of Krystal Biotech from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, April 9th. The Goldman Sachs Group boosted their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a "buy" rating in a report on Friday, January 30th. Wolfe Research began coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They set a "peer perform" rating for the company. Finally, HC Wainwright restated a "buy" rating and set a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $326.25.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.